AtriCure has demonstrated consistent earnings execution with three consecutive beats and substantial analyst upside of 46%, but a confirmed price downtrend and elevated options hedging create near-term headwinds that must resolve before the fundamental case translates into price appreciation.
Thesis pillars
- Earnings Beat Streak Execution→Stable
- Fcf Positive Despite Gaap Losses↑Improving
- Analyst Upside Favorable Asymmetry↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
AtriCure, Inc. (ATRC) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $40.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single and limited source third-party vendors; Analyst target reached - limited upside remaining.
AtriCure develops surgical devices for treating atrial fibrillation (Afib), left atrial appendage management, and post-operative pain, including its Isolator Synergy and EnCompass ablation clamps, AtriClip LAA exclusion system, and cryoICE/cryoSPHERE Cryo Nerve Block probes. The... Read more
Hold if already holding. Not a fresh buy at $40.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single and limited source third-party vendors; Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 74. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 89d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About AtriCure, Inc.
About AtriCure, Inc.
AtriCure's AtriClip left atrial appendage exclusion system has treated more than 750,000 patients worldwide, and the company expects its atrial fibrillation (Afib) ablation and left atrial appendage management (LAAM) products to continue generating a majority of revenue for the foreseeable future. AtriCure sells directly to hospitals in the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada, and through distributors elsewhere.
AtriCure generates revenue primarily from single-use disposable ablation and pain-management devices, including Isolator Synergy and EnCompass clamps, EPi-Sense catheters, and cryoICE cryoSPHERE and cryoXT Cryo Nerve Block probes, sold alongside capital equipment (RF and cryo generators) that the company places with hospital customers. Products reach the operating room through a direct sales force in AtriCure's core markets and through independent distributors in other international territories, a channel the 10-K flags as a distinct risk since distributor turnover can disrupt sales continuity. Manufacturing is concentrated at AtriCure's Ohio campus, with production and sterilization of key components handled by single and limited-source third-party vendors for the RF generator and EPi-Sense system. Reimbursement dynamics matter directly to adoption: procedure volumes depend on Medicare and private-payor coverage decisions, and AtriCure competes against catheter ablation, implantable devices, and pharmacological therapy for Afib patients.
Show full overview
AtriCure's supply chain carries concentrated single-source exposure: the 10-K states the company relies on single and limited source third-party vendors for manufacturing and sterilization of product components, as well as for its RF generator and EPi-Sense system, and describes "significant concentrations with a limited number of vendors." Switching suppliers could require product redesign and new FDA submissions, a process the filing calls time-consuming, while ethylene-oxide sterilization facilities used by these vendors have faced voluntary or regulator-mandated closures tied to emissions concerns. Because AtriCure also lacks a backup manufacturing facility outside its Ohio headquarters, a disruption at either the vendor or company level could delay product availability without a ready alternative.
See also: Healthcare · Medical Instruments & Supplies
From AtriCure, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-30Recent Developments — AtriCure, Inc.
Latest news
- NEWS AtriCure stock hits 52-week low at $27.04 By Investing.com - Investing.com Australia — Investing.com Australia negative
- NEWS AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low - What's Next? - MarketBeat — MarketBeat negative
- NEWS AtriCure stock hits 52-week low at $27.04 - Investing.com — Investing.com negative
- NEWS AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat — MarketBeat positive
- NEWS AtriCure (ATRC) Could Be 27% Undervalued Following Its Cardiac Device Growth Narrative - simplywall.st — simplywall.st positive
Generated 2026-07-31T00:08:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle and limited source third-party vendors10-K Item 1A: 'We rely on single and limited source third-party vendors for the manufacture and sterilization of components used in our products'
- MEDIUMProductablation and LAAM products10-K Item 1A: 'We expect that sales of our ablation and LAAM products will continue to account for a majority of our revenue for the foreseeable future'
- LOWcounterpartyindependent distributors10-K Item 1A: 'We depend on independent third-party distributors to sell our products in certain markets outside of the United States, and if these distributors do not perform, we may be unable to maintain or increase international revenue.'
Material Events(8-K, last 90d)
- 2026-05-19Item 5.02LOWAt the May 18, 2026 Annual Meeting, stockholders approved an amendment to the 2023 Stock Incentive Plan increasing shares available for issuance from 4,500,000 to 6,000,000. Routine compensation-plan matter; no leadership change.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $40.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single and limited source third-party vendors; Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 74. Maintain position. Not compelling to add more. Target $41.18 (+1.3%), stop $37.80 (−7.5%), A.R:R 0.1:1. Score 5.9/10, moderate confidence.
Take-profit target: $41.18 (+1.3% upside). Target $41.18 (+1.3%), stop $37.80 (−7.5%), A.R:R 0.1:1. Stop-loss: $37.80.
Concentration risk — Supplier: single and limited source third-party vendors; Analyst target reached - limited upside remaining.
AtriCure, Inc. trades at a P/E of 185.9 (forward 94.7). TrendMatrix value score: 4.8/10. Verdict: Hold.
16 analysts cover ATRC with a consensus score of 4.1/5. Average price target: $47.
What does AtriCure, Inc. do?AtriCure develops surgical devices for treating atrial fibrillation (Afib), left atrial appendage management, and...
AtriCure develops surgical devices for treating atrial fibrillation (Afib), left atrial appendage management, and post-operative pain, including its Isolator Synergy and EnCompass ablation clamps, AtriClip LAA exclusion system, and cryoICE/cryoSPHERE Cryo Nerve Block probes. The company sells directly to hospitals in the U.S., Germany, France, the UK, the Benelux region, Australia, and Canada, and through distributors elsewhere, with ablation and LAAM products expected to continue generating a majority of revenue. AtriCure's AtriClip is the most widely sold LAA management device worldwide, wit